Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells
The Kaohsiung Journal of Medical Sciences · 2024
DOI: 10.1002/kjm2.12835 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Kaohsiung Journal of Medical Sciences, 2024. Verfasst von Yi-Ching Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Bortezomib, Cell Movement, Cell Proliferation, Reactive Oxygen Species. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kaohsiung Medical University Chung-Ho Memorial Hospital, National Science and Technology Council, Taiwan, National Science and Technology Council.
Abstract (Originalsprache)
Pulmonary vascular remodeling is a key pathological process of pulmonary arterial hypertension (PAH), characterized by uncontrolled proliferation and migration of pulmonary arterial smooth muscle cells (PASMCs). Bortezomib (BTZ) is the first Food and Drug Administration (FDA)‐approved proteasome inhibitor for multiple myeloma treatment. Recently, there is emerging evidence showing its effect on reversing PAH, although its mechanisms are not well understood. In this study, anti‐proliferative and anti‐migratory effects of BTZ on PASMCs were first examined by different inducers such as fetal bovine serum (FBS), angiotensin II (Ang II) and platelet‐derived growth factor (PDGF)‐BB, while potential mechanisms including cellular reactive oxygen species (ROS) and mitochondrial ROS were then investigated; finally, signal transduction of ERK and Akt was examined. Our results showed that BTZ attenuated FBS‐, Ang II‐ and PDGF‐BB‐induced proliferation and migration, with associated decreased cellular ROS production and mitochondrial ROS production. In addition, the phosphorylation of ERK and Akt induced by Ang II and PDGF‐BB was also inhibited by BTZ treatment. This study indicates that BTZ can prevent proliferation and migration of PASMCs, which are possibly mediated by decreased ROS production and down‐regulation of ERK and Akt. Thus, proteasome inhibition can be a novel pharmacological target in the management of PAH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Medical Research, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan.
- Department of Pediatrics, Chi-Mei Medical Center, Tainan, Taiwan.
- School of Medicine, College of Medicine, National Sun Yat-sen University, Kaohsiung, Taiwan.
- School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Department of Childhood Education and Nursery, Chia Nan University of Pharmacy and Science, Tainan, Taiwan.
ORCID-Profile: Yu-Hsin Tseng, Jong-Hau Hsu
Förderung
- Kaohsiung Medical University Chung-Ho Memorial Hospital
- National Science and Technology Council, Taiwan
- National Science and Technology Council
Zitieren
APA
Liu, Y. C., Tseng, Y. H., Kuan, Y. H., Wang, L. Y., Huang, S. E., Tsai, S. P., Yeh, J. L., & Hsu, J. H. (2024). Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells. The Kaohsiung Journal of Medical Sciences. https://doi.org/10.1002/kjm2.12835
Vancouver
Liu YC, Tseng YH, Kuan YH, Wang LY, Huang SE, Tsai SP, et al. Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells. The Kaohsiung Journal of Medical Sciences. 2024. doi:10.1002/kjm2.12835
BibTeX
@article{Liu2024,
author = {Liu, Yi-Ching and Tseng, Yu-Hsin and Kuan, Yu-Hsin and Wang, Lin-Yen and Huang, Shang-En and Tsai, Siao-Ping and Yeh, Jwu-Lai and Hsu, Jong-Hau},
title = {Proteasome inhibitor bortezomib prevents proliferation and migration of pulmonary arterial smooth muscle cells},
journal = {The Kaohsiung Journal of Medical Sciences},
year = {2024},
doi = {10.1002/kjm2.12835}
}
EUVIMED